If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially as antibiotic resistance grows. While it’s currently approved for females ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the treatment of uncomplicated urinary tract infections (UTIs) in women aged 12 ...

GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...

The drug, known in development as gepotidacin, will be marketed under the brand name Blujepa. GSK said it plans to launch the new product in the second half of this year. Uncomplicated UTIs are ...

The FDA has approved GSK's gepotidacin (Blujepa) for treating uncomplicated urinary tract infections (uUTIs) in females aged 12 and older. The approval is based on successful phase 3 EAGLE-2 and EAGLE ...

The FDA has approved GSK’s gepotidacin, the first antibiotic for uncomplicated urinary tract infections in 30 years. The drug has been approved for female adults and adolescents with UTIs caused by ...

The drug chemically known as gepotidacin is designed to target the most common UTI-causing bacteria such as E. coli, the company said. The drug acts on a different part of the bacteria compared to ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...